Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Major Depressive Disorder
- Sponsor
- Brown University
- Enrollment
- 62
- Locations
- 1
- Primary Endpoint
- Treatment Acceptability
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to conduct a randomized pilot trial in a sample of 60 women who meet criteria for Major Depressive Disorder (MDD) 1-18 months after a perinatal loss to demonstrate the feasibility of the proposed recruitment methods and research design, of the therapist training methods, and of delivering the adapted Interpersonal Psychotherapy group treatment.
The investigators would like to examine preliminary evidence for the following hypotheses:
- Perinatal-loss specific IPT-G will be more acceptable to women who experience MDD following perinatal loss than will Coping with Depression (CWD).
- Perinatal-loss specific IPT-G will result in reduced time to remission from MDD and reduced depressive symptoms relative to CWD.
- Perinatal-loss specific IPT-G will result in increased social support and social functioning, reduced couple distress, and reduced grief relative to CWD.
Investigators
Dr. Jennifer Johnson
Associate Professor (Research)
Brown University
Eligibility Criteria
Inclusion Criteria
- •Current Major Depressive episode.
- •Experience perinatal loss 1-18 months prior to intake (including early and late fetal death and the death of a live born neonate within the first 28 days).
Exclusion Criteria
- •Untreated thyroid difficulties (TSH levels out of the normal range).
- •Anemia (hemoglobin or hematocrit out of the normal range).
- •Onset of current major depressive episode prior to news of difficulties with the pregnancy or health risk to the infant (women with prior episodes will be included).
- •Current or past diagnosis of bipolar I disorder, schizophrenia or other psychotic disorder.
- •Primary diagnosis of substance dependence or eating disorder.
- •Acute suicidal or homicidal risk.
- •Non-stable course of antidepressant medication or psychotherapy (i.e., beginning or changing dose of either within the previous 8 weeks).
- •Any IPT or cognitive-behavioral treatment in the previous 8 weeks.
Outcomes
Primary Outcomes
Treatment Acceptability
Time Frame: Post Treatment (12 Weeks)
Treatment acceptability measured by the End of Treatment Questionnaire and the client satisfaction questionnaire.
Reduced time to remission from major depressive disorder (exploratory in this underpowered feasibility/acceptability study)
Time Frame: Survival analysis
We will calculate the effect size and confidence intervals for time to remission from depressive episode. Remission will be defined as number of weeks until Hamilton Rating Scale for Depression score of 7 or less. Recovery from major depression is an exploratory aim; it will be defined as 8+ consecutive weeks on the Longitudinal Interval Follow-up Evaluation PSR scores of 1 or 2. Exploratory tests for differences between conditions will use Cox regression, with initial HRSD scores as a covariate.
Reduction in depressive symptoms (exploratory in this underpowered feasibility/acceptability study)
Time Frame: Slopes over time
We will calculate the effect sizes and confidence intervals for reduction in depressive symptoms using HRSD and BDI-II scores. Exploratory tests for differences between conditions will use HLM with baseline scores as covariates.
Secondary Outcomes
- Perceived Social Support(Slope over time: Baseline, 4 Weeks, 8 Weeks, 12 Weeks, 3 Months, 6 Months)
- Grief(Slope over time: Baseline, 4 Weeks, 8 Weeks, 12 Weeks, 3 Months, 6 Months)
- Couple Distress(Slope over time: Baseline, 4 Weeks, 8 Weeks, 12 Weeks, 3 Months, 6 Months)